Akari Therapeutics PLC 8-K filings

Akari Therapeutics, Plc has announced a merger agreement with Peak Bio, Inc., aiming to combine their resources and pipelines.

Akari Therapeutics has finalized a separation agreement with its former CEO, Rachelle Jacques, including a $450,000 payment and vesting of certain stock units.

Akari Therapeutics announced its second quarter 2024 financial results, a strategic shift to focus on its ADC platform and geographic atrophy program, and secured $7.6 million in financing.

Akari Therapeutics successfully held its adjourned Annual General Meeting on June 28, 2024, where all proposed resolutions were approved and director nominees were elected after an initial meeting failed to reach a quorum.

Akari Therapeutics has appointed Samir R. Patel, M.D., as Interim President and Chief Executive Officer, with compensation entirely in the form of fully vested ordinary shares.

Akari Therapeutics has successfully completed a private placement, raising approximately $7.6 million through the sale of American Depository Shares and warrants.

Akari Therapeutics has entered a merger agreement with Peak Bio, reported its Q1 2024 financial results, and announced a restructuring plan.

Akari Therapeutics is reducing its workforce by approximately 67% and restructuring operations following the suspension of its HSCT-TMA program, also a board member has resigned.

Akari Therapeutics has announced the departure of its CEO and COO, the appointment of an interim CEO, and a strategic portfolio prioritization following its merger agreement with Peak Bio.

Akari Therapeutics has received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement, placing its listing status at risk.

Akari Therapeutics reported its full-year 2023 financial results, highlighted by a merger agreement with Peak Bio and advancements in its clinical programs.

Akari Therapeutics has entered into a definitive agreement for a private placement of approximately $1.615 million of American Depository Shares (ADS) with existing investors, concurrent with its proposed merger with Peak Bio, Inc.

Akari Therapeutics and Peak Bio have agreed to merge in an all-stock transaction, creating a combined entity with an expanded pipeline and a focus on business development and licensing.